Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Centessa Pharmaceuticals (Nasdaq: CNTA) announced proof-of-mechanism data from its Phase 1 study of ZF874 for treating Alpha-1 Antitrypsin Deficiency (AATD). The study showed increases in functional Z-A1AT levels exceeding 11 micromolar in patients with the PiZZ genotype. One subject displayed reversible elevation in liver enzymes, prompting the company to expedite enrollment for upcoming studies. The expected Phase 2 study is set to refine dosing and is anticipated to start in 2Q 2022.

Centessa Pharmaceuticals (CNTA) and Schrödinger are collaborating to discover novel therapeutics targeting the orexin-2 receptor (OX2R), which plays a critical role in sleep disorders like narcolepsy. This partnership allows Orexia to utilize Schrödinger’s advanced computational platform, enhancing drug discovery capabilities. Orexia aims to leverage this collaboration for the development of orexin agonists addressing narcolepsy type 1 and other conditions characterized by excessive daytime sleepiness. The agreement includes milestone payments and royalties for Schrödinger.

Schrödinger (Nasdaq:SDGR) and Centessa Pharmaceuticals (Nasdaq:CNTA) announced an exclusive collaboration to discover novel therapeutics targeting the orexin-2 receptor (OX2R), relevant for sleep disorders like narcolepsy. This partnership marks the first large-scale application of Schrödinger's computational platform in orexin agonist development, leveraging Orexia’s structural biology capabilities. Orexia will manage preclinical research and commercialization, while Schrödinger will receive upfront payments and potential royalties on global sales. The collaboration aims to explore orexin agonists for various disorders characterized by excessive daytime sleepiness.

Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed David Grainger, PhD, as its new Chief Innovation Officer, enhancing its executive leadership team. Dr. Grainger, a key advisor since the company's formation, will oversee scientific and research activities, shaping the development of therapeutic candidates. His appointment aligns with Centessa's goals for clinical and pre-clinical milestones. Previously, Dr. Grainger co-founded 28 biotech companies and has extensive experience in drug development.

Centessa Pharmaceuticals has announced a $300 million financing agreement with Oberland Capital, significantly boosting its available capital to over $900 million. This funding will support the advancement of its clinical and pre-clinical programs and enable strategic business development. The financing structure includes interest-only senior secured notes for six years. The initial $75 million was funded on October 4, 2021, with further options for funding available. This strategic move comes after a positive Phase 2 trial readout and sets the stage for potential registrational studies.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive topline results from the Phase 2a trial of SerpinPC, a treatment for severe hemophilia A and B. The study showed an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% for spontaneous joint bleeds in the highest dose tested. The drug was found to be well-tolerated, with minimal adverse events reported. The company plans to initiate a global registrational program and will host a conference call to discuss findings.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET. A live audio webcast will be available on the investor relations section of Centessa's website, with a replay accessible for 90 days post-event. Centessa focuses on bringing new medicines to patients through a specialized, asset-centric approach, targeting various therapeutic areas such as oncology and immunology.

Centessa Pharmaceuticals (NASDAQ: CNTA) successfully completed an initial public offering (IPO), raising gross proceeds of $379.5 million to support its clinical and preclinical programs. The leadership team has been strengthened with key appointments in various executive roles. Financial results for Q2 2021 show a cash position of $613.8 million, enabling operations through the end of 2023. R&D expenses rose to $18.1 million due to an expanded portfolio, while net loss increased to $41.5 million or $0.65 per share.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET. The company focuses on developing new medicines through an asset-centric model, emphasizing specialized teams for diverse therapeutic areas, including oncology, hematology, and immunology. Centessa owns ten asset-centric companies, ranging from discovery to late-stage development, allowing for strategic resource allocation and shared infrastructure.